Nektar Therapeutics (NKTR) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Nektar Therapeutics (NKTR) PT Raised to $35 at Jefferies; Plans '181 NDA 2 Years Early
November 8, 2017 8:28 AM ESTJefferies raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $23.00) while maintaining a Buy rating following Q3 results.
Analyst David Steinberg said the big news was NKTR disclosed that they are now planning to file an NDA for 181 in Apr... More
